An AI-Designed Drug Just Made Lung Disease Patients Biologically Years Younger

A Drug That Fights Lung Disease — and Aging at the Same Time

What if a drug built to treat a fatal lung condition turned out to also wind back the biological clock? That's the striking question raised by new research published this week in Nature Biotechnology. A small-molecule drug designed entirely by artificial intelligence has produced some of the most compelling clinical evidence yet that pharmacological intervention can reverse markers of biological aging — with Insilico Medicine's experimental compound rentosertib reducing patients' predicted biological age by up to six years after just four weeks of treatment.

The findings come from a secondary analysis of blood samples collected during a Phase 2a trial for idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease. Forty-two participants consented to longitudinal proteomic profiling, which measured 2,841 proteins at baseline and at weeks two, four, and twelve. The cohort had a mean age of 67.1 years. These were not young, healthy volunteers — they were older patients battling a serious illness. That makes the results all the more remarkable.

Six Independent Clocks, One Consistent Signal

Researchers ran serum samples from the 42 IPF patients through six aging clocks developed by independent research groups at institutions including Insilico, Harvard, Oxford, and Peking University. Using multiple clocks was a deliberate safeguard against a fluke. Six independent models pointing in the same direction suggest a genuine signal rather than an artifact of any single clock.

Patients who received rentosertib showed a lower biological age than at baseline, while the placebo group remained stable or aged slightly. The effect was greatest in the group receiving 30 mg twice daily, where biological age fell by approximately three to four years after four weeks, and by up to six years according to one of the clocks. Those given a placebo saw little change in their biological age on those same clocks. "If your biological age is lower, you are likely to die later," said Insilico CEO Alex Zhavoronkov.

Built by AI, From the Ground Up

What sets rentosertib apart isn't just the results — it's how the drug was made. The study represents the first clinical evaluation of a potentially first-in-class drug candidate featuring both an AI-discovered target with relevance to aging and disease biology and an AI-designed molecule, rather than a repurposed generic drug such as rapamycin or metformin. Using its AI-powered target discovery platform, Insilico identified TNIK as a novel target implicated in aging and fibrosis. TNIK was subsequently prioritized as a dual-purpose target relevant to both underlying aging biology and IPF, and Insilico's generative chemistry platform, Chemistry42, was then deployed to design the small-molecule candidate rentosertib.

The program progressed from target identification to preclinical candidate nomination in about 18 months — a timeline that would be nearly impossible using traditional drug discovery methods. The findings also provide a proof-of-concept framework for integrating aging biomarkers into standard clinical trials to accelerate the discovery of geroprotective drugs and longevity therapeutics.

Promising, But the Bigger Test Is Still Ahead

Zhavoronkov cautioned that the results are still early and the long-term health effects of the drug on larger groups of people are unknown. The study was small — just 42 patients — and the aging analysis was a secondary endpoint, not the primary goal of the trial. Independent scientists and regulators will want to see these results replicated at much greater scale before drawing sweeping conclusions about anti-aging potential.

Rentosertib has now advanced to a Phase 3 trial in IPF. That study, initiated in July 2026 across 47 centers in China, will enroll approximately 320 patients and track the annual rate of decline in forced vital capacity over 52 weeks. Whether rentosertib ultimately proves useful for longevity remains an open question. But the company's approach — embedding geroscience endpoints into disease-focused trials — represents a template other drug developers may follow. If that template catches on, we may be entering an era where treating disease and slowing aging are no longer separate goals, but the same one.